Imfinzi (Durvalumab)

Durvalumab is a monoclonal antibody that binds to the programmed death‑ligand 1 (PD‑L1) protein on tumor and immune cells. By blocking PD‑L1’s interaction with PD‑1 and CD80 receptors, it lifts the inhibitory signal that normally dampens T‑cell activity, allowing the immune system to recognize and attack cancer cells more effectively.

The dosing regimen for Imfinzi is determined by the prescribing oncologist based on the specific indication, patient weight, and clinical condition. It is administered as an intravenous infusion in a healthcare setting, and the prescriber will set the exact dose, frequency, and duration according to approved labeling and individual patient needs.

Safety data for Imfinzi during pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should discuss contraception and breastfeeding considerations with their healthcare provider.

To order Imfinzi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, cold‑chain shipping details (if applicable), and assists with any required import documentation.

Imfinzi (durvalumab) belongs to the same class of PD‑L1 inhibitors as atezolizumab and avelumab. All three block the PD‑L1 pathway, but they differ in approved indications, dosing schedules, and trial data. Imfinzi is uniquely approved for maintenance therapy after chemoradiotherapy in stage III NSCLC, while the others have distinct label‑specific uses.

Imfinzi must be stored refrigerated at 2‑8 °C (36‑46 °F). It should be kept in its original carton to protect from light, must not be frozen, and should not be shaken. Prior to infusion, the solution may be allowed to reach room temperature, but any deviation from the recommended temperature range can affect product stability.

Imfinzi is given as an intravenous infusion in a clinical setting. The infusion is typically administered over 60 minutes, although the exact rate and duration are determined by the prescribing physician and institutional protocols. Patients are monitored during and after the infusion for any infusion‑related reactions or adverse events.

The most serious risks associated with Imfinzi include immune‑mediated pneumonitis, hepatitis, colitis, and endocrine disorders such as hypothyroidism or adrenal insufficiency. These conditions can be severe or life‑threatening and require prompt medical evaluation. Patients should be educated to report new respiratory symptoms, abdominal pain, jaundice, or hormonal changes immediately.

Imfinzi is contraindicated in patients with known hypersensitivity to durvalumab or any of its excipients. Caution is advised for individuals with active autoimmune diseases, uncontrolled infections, or those receiving live vaccines. The drug should also be avoided in patients who are pregnant or breastfeeding unless the potential therapeutic benefit outweighs the possible risks.